(Q39435774)

11 September 2017

FP3: a novel VEGF blocker with antiangiogenic effects in vitro and antitumour effects in vivo (English)

1 reference

11 September 2017

angiogenesis inhibitor

1 reference

K Jin

1

1 reference

11 September 2017

K He

2

1 reference

11 September 2017

F Teng

3

1 reference

11 September 2017

G Li

4

1 reference

11 September 2017

H Wang

5

1 reference

11 September 2017

N Han

6

1 reference

11 September 2017

Z Xu

7

1 reference

11 September 2017

J Cao

8

1 reference

11 September 2017

J Wu

9

1 reference

11 September 2017

D Yu

10

1 reference

11 September 2017

L Teng

11

1 reference

11 September 2017

1 December 2011

1 reference

Clinical and Translational Oncology

11 September 2017

1 reference

11 September 2017

13

1 reference

11 September 2017

878-884

1 reference

11 September 2017

12

1 reference

https://scigraph.springernature.com/pub.10.1007/s12094-011-0749-z

11 September 2017

0 references

cites work

Angiogenesis in cancer and other diseases

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

Structure and function of VEGF/VEGF-receptor system involved in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

The potential of antiangiogenic therapy in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

Advances in combination of antiangiogenic agents targeting VEGF-binding and conventional chemotherapy and radiation for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

Clinical applications of VEGF-trap (aflibercept) in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

Antiangiogenic effect of deguelin on choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

Downregulation of VEGF-D expression by interleukin-1beta in cardiac microvascular endothelial cells is mediated by MAPKs and PKCalpha/beta1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: A comparative study of angiogenesis in Matrigel, collagen, fibrin, and plasma clot

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

Current methods for assaying angiogenesis in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

Clinical and biological significance of vascular endothelial growth factor in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

Bevacizumab for patients with metastatic renal cancer: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

VEGF receptor signaling in tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0749-Z

Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22126731

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12094-011-0749-Z

1 reference

11 September 2017

1 reference